binimetinib

Phase 3

PFIZER (PFE)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in MSS

View Full Landscape

Drug Information

Target Indication

MSS

Clinical Trial

NCT03271047

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Balimek

Treatment of unresectable or metastatic melanoma. Treatment of unresectable melanoma, with NRA Q61 mutation.

View on EMA

EMA9/20/2018

Mektovi

MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus